Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
This article analyses the effectiveness, clinical outcomes, and safety of mepolizumab in clinical practice.
Back to homepage
Respiratory
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.
Agents to treat BRAF-mutant lung cancer
Keywords: dabrafenib, immunotherapy, lung neoplasm, protooncogene protein B-raf, trametinib. Citation: Bustamante Alvarez JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs in Context 2019; 8: 212566. DOI: 10.7573/dic.212566 Contributions: Both authors contributed equally to the preparation of this review.
Severe refractory asthma: current treatment options and ongoing research
In this review, the different biological options available for the treatment of severe refractory asthma, their mechanism of action, and the overlapping aspects of their usage in clinical practice are discussed.
Sublingual allergen immunotherapy for respiratory allergy: a systematic review
This systematic review provides complete and updated information on efficacy and safety of sublingual immunotherapy (SLIT) formulations for the treatment of allergic respiratory diseases (ARDs).
